, Tracking Stock Market Picks
Enter Symbol:
Alkermes, Inc. (ALKS) [hlAlert]

down 44.67 %

Alkermes, Inc. (ALKS) downgraded to Sell by MKM Partners

Posted on: Friday,  May 24, 2013  11:25 AM ET by MKM Partners

MKM Partners rated Sell Alkermes, Inc. (NASDAQ: ALKS) on 05/24/2013, when the stock price was $33.84. Since
then, Alkermes, Inc. has gained 80.76% as of 01/21/2016's recent price of $61.17.
If you would have followed this MKM Partners's recommendation on ALKS, you would have lost 44.67% of your investment in 972 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

MKM Partners LLC is an institutional equity trading and research firm. MKM Partners has extensive experience in the agency execution of U.S. and international equity orders. We provide clients with timely and unbiased economic, technical, and fundamental research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/28/2014 11:25 AM Sell
51.18 32.00
as of 12/13/2013
1 Week up  0.87 %
1 Month down  -5.19 %
3 Months down  -15.22 %
1 YTD up  1.74 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/24/2013 11:25 AM Sell
4/17/2013 11:25 AM Hold
28.49 25.00
1/23/2013 11:25 AM Hold
1/25/2012 11:25 AM Buy
18.55 20.00
6/21/2011 8:25 AM Buy
17.59 20.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy